# AI-Based Early Cancer Detection: A Comparative Analysis of Imaging, Genomics, and Multimodal Approaches

---

## Executive Summary

Artificial intelligence (AI) is transforming early cancer detection by enabling high-throughput, objective analysis of complex biological data. This report synthesizes evidence from 117 peer-reviewed studies retrieved across five academic databases (SciSpace, Google Scholar, PubMed, ArXiv, and SciSpace Full Text) to compare the performance of three major AI-driven paradigms: **(1) imaging-based**, **(2) genomics-based**, and **(3) multimodal fusion** approaches. Performance is benchmarked using Area Under the Receiver Operating Characteristic Curve (AUC), sensitivity, and specificity.

Key findings indicate that imaging-based AI achieves AUCs of 0.63–0.97 depending on modality and cancer type; genomics-based AI approaches report single-study AUCs as high as 0.98 but lack large-scale prospective validation; and multimodal fusion systems consistently outperform single-modality approaches, with AUCs reaching 0.96–0.98 and sensitivity/specificity above 90%. A direct radiogenomic comparison in lung cancer demonstrated that fusion (AUC 96.3%) surpassed imaging-alone (91.8%) and genomics-alone (89.7%), underscoring the additive value of data integration.

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Methodology](#2-methodology)
3. [Imaging-Based AI Approaches](#3-imaging-based-ai-approaches)
4. [Genomics-Based AI Approaches](#4-genomics-based-ai-approaches)
5. [Multimodal AI Approaches](#5-multimodal-ai-approaches)
6. [Comparative Performance Analysis](#6-comparative-performance-analysis)
7. [Challenges and Limitations](#7-challenges-and-limitations)
8. [Future Directions](#8-future-directions)
9. [Conclusion](#9-conclusion)
10. [References](#10-references)

---

## 1. Introduction

Cancer remains one of the leading causes of mortality worldwide, with early detection being the most critical factor in improving patient outcomes. Conventional screening programs—mammography for breast cancer, low-dose CT for lung cancer, PSA testing for prostate cancer—have demonstrated efficacy but are constrained by high false-positive rates, operator variability, and limited scalability.

Artificial intelligence, particularly deep learning and ensemble machine learning, has emerged as a powerful augmentation to these workflows. AI systems can detect subtle patterns in medical images, genomic sequences, and proteomic profiles that may elude human observers, offering the potential to flag malignancies at earlier, more treatable stages.

This report examines the state of the art across three AI paradigms for early cancer detection:
- **Imaging-based AI**: Convolutional neural networks (CNNs) and radiomics applied to mammography, CT, MRI, and digital pathology.
- **Genomics-based AI**: Machine learning applied to liquid biopsy, cell-free DNA (cfDNA), surface-enhanced Raman spectroscopy (SERS), and proteomic markers.
- **Multimodal AI**: Fusion architectures that integrate imaging with genomic, clinical, and demographic data.

---

## 2. Methodology

### 2.1 Literature Search Strategy

A systematic search was conducted across five databases:
- **SciSpace** (semantic and full-text search)
- **Google Scholar**
- **PubMed**
- **ArXiv**

**Search terms**: AI-based early cancer detection, AUC sensitivity specificity, imaging genomics multimodal deep learning machine learning performance comparison.

**Results**: 260 total papers retrieved; 117 unique papers after deduplication, ranked by relevance.

### 2.2 Inclusion Criteria

| Criterion | Detail |
|-----------|--------|
| Study type | Original research, systematic reviews, meta-analyses |
| AI modality | Imaging, genomics/omics, or multimodal/fusion |
| Outcome | AUC, sensitivity, specificity, or accuracy reported |
| Cancer focus | Any cancer type with early detection context |
| Publication period | 2020–2026 (emphasis on 2023–2026) |

### 2.3 Performance Metrics Defined

| Metric | Definition |
|--------|-----------|
| **AUC** | Area Under ROC Curve; 1.0 = perfect discrimination |
| **Sensitivity** | True positive rate; proportion of cancers correctly identified |
| **Specificity** | True negative rate; proportion of non-cancers correctly excluded |
| **Accuracy** | Overall proportion of correct classifications |

---

## 3. Imaging-Based AI Approaches

### 3.1 Overview

Imaging-based AI systems are the most clinically mature of the three paradigms. They apply CNNs, radiomics pipelines, and ensemble classifiers to radiological and pathological images. Large-scale deployment studies and head-to-head comparisons with radiologists have been reported, particularly in breast and lung cancer screening [1][2][3].

### 3.2 Key AI Architectures

| Architecture | Application | Description |
|-------------|-------------|-------------|
| Convolutional Neural Networks (CNNs) | Mammography, CT, MRI | End-to-end feature extraction from pixel data |
| Radiomics | CT, MRI | Quantitative feature extraction from regions of interest |
| Ensemble/Classical ML | Screening programs | Random forests, SVMs on extracted features |
| Transformer-based models | Pathology, MRI | Attention mechanisms for global context |

### 3.3 Performance by Cancer Type

| Cancer Type | Imaging Modality | AI Method | AUC | Sensitivity | Specificity | Reference |
|-------------|-----------------|-----------|-----|-------------|-------------|-----------|
| Breast | Mammography + Ultrasound (multimodal imaging) | Deep learning fusion | **0.968** | — | 96.41% | [5] |
| Breast | Screening mammography (longitudinal) | AI CAD | 0.63–0.67 | 13–25% (pre-diagnostic) | Fixed 90% | [6] |
| Prostate | mpMRI | CNN ensemble | **0.88** (median) | 86% (median) | 83% (median) | [4] |
| Lung | CT nodule detection | CNN vs. radiologist | Varies | Improved vs. baseline | Variable | [2] |
| Breast (international) | Mammography | Deep learning | Non-inferior to radiologists | Reduced reader workload | High | [3] |

> **Note**: AUC 0.63–0.67 for longitudinal mammography AI reflects detection of cancers *years before* clinical diagnosis — a fundamentally harder task than standard screening.

### 3.4 Strengths

- Largest volume of clinical validation data
- Direct comparison with radiologist performance available [3]
- Regulatory-cleared AI tools exist (FDA-cleared CAD systems)
- Applicable to population-scale screening programs

### 3.5 Limitations

- **Dataset heterogeneity** across scanners, institutions, and annotation protocols reduces generalizability [4][2]
- **Specificity variability** — false positives remain a persistent challenge [2][6]
- **Limited prospective validation** in real-world screening workflows [4][3]
- Performance degrades for rare cancers with limited training data

---

## 4. Genomics-Based AI Approaches

### 4.1 Overview

Genomics-based AI leverages molecular signals — including cfDNA methylation, serum proteomics, urine biomarkers, and spectroscopic fingerprints — to detect cancer-derived signatures in blood or urine. These approaches are particularly promising for multi-cancer early detection (MCED) as they are non-invasive and cancer-type agnostic [10].

### 4.2 Key AI Architectures

| Architecture | Application | Description |
|-------------|-------------|-------------|
| Random Forest / Gradient Boosting | cfDNA, multi-omics | Tabular genomic feature classification |
| 1D-CNN + LSTM | Proteomic/spectral signals | Sequential pattern recognition in biomarker arrays |
| Multivariate ML classifiers | SERS fingerprints | Spectral perturbation decoding |
| Deep neural networks | Multi-cancer panels | High-dimensional omics integration |

### 4.3 Performance by Cancer Type and Biomarker

| Cancer Type | Biomarker/Method | AI Method | AUC | Sensitivity | Specificity | Reference |
|-------------|-----------------|-----------|-----|-------------|-------------|-----------|
| NSCLC (Lung) | SERS serum artificial nose | ML spectral classifier | — | **100%** | **98%** | [9] |
| Pancreatic (PDAC) | Urine proteomics | 1D-CNN + LSTM | **0.98** | — | Accuracy 97% | [8] |
| Multi-cancer | Blood cfDNA/methylation (MCED) | Ensemble ML | Up to **0.993** | Variable | Variable | [11] |
| Various | Genomic/omics AI (meta-analysis) | Multiple | ~0.90–0.993 | High (best-case) | High (best-case) | [11] |

> ⚠️ **Caution**: Very high AUCs (>0.99) in genomics studies often reflect small, homogeneous cohorts with potential overfitting. Large-scale prospective replication is critical.

### 4.4 Strengths

- **Minimally invasive** — blood or urine samples only
- **Pan-cancer potential** — single assay can screen for multiple cancer types
- **Early-stage signal** — can detect molecular alterations before imaging-detectable lesions
- High AUCs in controlled study settings

### 4.5 Limitations

- **Small cohort sizes** and risk of overfitting in high-performance reports [10][11]
- **Lack of large prospective validation** — most MCED tests are not yet clinically validated at population scale [10]
- **Assay standardization** challenges across platforms and laboratories [10]
- **Tissue-of-origin prediction** accuracy varies; misclassification can misdirect workup

---

## 5. Multimodal AI Approaches

### 5.1 Overview

Multimodal AI systems integrate data from two or more sources — typically combining imaging with genomic, clinical, or demographic data — using fusion architectures. These systems consistently demonstrate performance gains over single-modality approaches [7][12][13][14].

### 5.2 Key AI Architectures

| Architecture | Description | Application |
|-------------|-------------|-------------|
| 3D CNN + Clinical Branch | Separate imaging and tabular encoders, fused via fully connected layers | Lung CT + biomarkers + demographics |
| Cross-modal Attention | Attention weights modulate inter-modality feature importance | Radiogenomics |
| Semi-supervised Deep Fusion | Label-efficient training across modalities | Cervical cancer (histology + genomics + clinical) |
| SHAP-guided Ensemble | Explainability-driven feature fusion | Lung radiogenomics |

### 5.3 Performance by Cancer Type

| Cancer Type | Modalities Fused | AI Architecture | AUC | Sensitivity | Specificity | Reference |
|-------------|-----------------|-----------------|-----|-------------|-------------|-----------|
| Cervical | Histopathology + Genomics + Clinical | Semi-supervised deep fusion | **0.98** | **96%** | **94%** | [14] |
| Lung | Low-dose CT + Biomarkers + Demographics | LungGuard 3D-CNN fusion | **0.96** | **~92%** | **~90%** | [12] |
| Lung | CT imaging + Gene expression | SHAP-guided RF + CNN fusion | **0.963** | — | — | [7] |
| Cervical | Visual + Genomic + Clinical | Multimodal AI | High | High | High | [13] |

### 5.4 Strengths

- **Consistently highest performance** vs. single-modality approaches
- **Additive information gain** — imaging captures spatial/morphological features; genomics captures molecular alterations
- **Robustness** — missing modality handling possible with imputation/masking strategies
- **Explainability** — SHAP and attention maps enable clinical interpretability [7]

### 5.5 Limitations

- **Integration complexity**: synchronizing heterogeneous data types, missing modalities, and multi-site alignment [12][14]
- **Data governance and labeling costs**: requiring paired imaging + molecular data significantly reduces available training cohorts
- **Computational overhead**: 3D CNN + fusion pipelines require substantial GPU resources
- **Prospective trials needed**: most gains demonstrated on retrospective datasets [12][13]

---

## 6. Comparative Performance Analysis

### 6.1 Summary Performance Table

| Approach | Best AUC | Best Sensitivity | Best Specificity | Cancer Type | Validation Scale |
|----------|---------|-----------------|-----------------|-------------|-----------------|
| **Imaging-based** | 0.968 | 86% (median, prostate) | 96.41% (breast imaging) | Breast, Lung, Prostate | Large (population-scale) |
| **Genomics-based** | 0.98–0.993 | 100% (NSCLC SERS) | 98% (NSCLC SERS) | NSCLC, PDAC, Multi-cancer | Small–medium cohorts |
| **Multimodal fusion** | 0.98 | 96% (cervical) | 94% (cervical) | Cervical, Lung | Medium (multi-centre) |

### 6.2 Head-to-Head Comparison: Lung Radiogenomics

The most informative direct comparison available in the literature is a SHAP-guided radiogenomic study in lung cancer [7]:

| Modality | AUC |
|---------|-----|
| Imaging alone (CT-CNN) | 91.8% |
| Genomics alone (gene expression RF) | 89.7% |
| **Multimodal fusion** | **96.3%** |

This demonstrates a **+4.5 percentage point gain** from fusion over the best single modality — a clinically meaningful improvement in early detection discriminative power.

### 6.3 Performance Radar Overview

```
                  AUC
                   ▲
                   │
     Multimodal ●──┼──● Genomics
                   │
                   │
              Imaging ●
                   │
                   └──────────────► Clinical Validation Scale
```

- **Genomics**: Highest peak AUC in controlled studies, lowest clinical validation scale
- **Imaging**: Moderate-to-high AUC, highest clinical validation scale
- **Multimodal**: Highest AUC with moderate clinical validation scale — the most promising frontier

### 6.4 Approach Comparison Matrix

| Dimension | Imaging | Genomics | Multimodal |
|-----------|---------|----------|------------|
| AUC range | 0.63–0.97 | 0.90–0.993 | 0.96–0.98 |
| Sensitivity range | 13–100% (task-dependent) | High (small cohorts) | ~90–96% |
| Specificity range | 83–96% | 83–98% | ~90–94% |
| Clinical maturity | ★★★★☆ | ★★☆☆☆ | ★★★☆☆ |
| Invasiveness | Non-invasive | Minimally invasive | Varies |
| Data requirements | Imaging archives | Biobank + assay data | Both + clinical |
| Scalability | High | Medium | Low–Medium |
| Explainability | Medium (GradCAM) | Low–Medium | Medium (SHAP/attention) |
| Regulatory approval | Partial (FDA CADs) | Limited | None yet |

---

## 7. Challenges and Limitations

### 7.1 Common Challenges Across All Approaches

| Challenge | Description |
|-----------|-------------|
| **Dataset heterogeneity** | Differences in scanners, populations, annotation protocols, and assay platforms limit cross-study comparability [4][2][10] |
| **Prospective validation gap** | Most high-performing models are validated retrospectively; prospective, randomized clinical trials are rare [10][12][4] |
| **Overfitting risk** | Small cohorts relative to model complexity inflate reported performance, especially in genomics [10][11] |
| **Generalizability** | Models trained on single-institution data often underperform on external datasets [3][4] |
| **Regulatory pathway** | AI-based cancer screening tools face complex regulatory requirements; few have achieved broad clinical approval |

### 7.2 Approach-Specific Challenges

**Imaging**: False-positive rates in CT lung nodule detection and mammography remain clinically significant, leading to unnecessary biopsies and patient anxiety [2][6].

**Genomics**: Assay standardization across platforms, preanalytic variability in sample handling, and tissue-of-origin misclassification in MCED tests are key barriers to clinical deployment [10].

**Multimodal**: Requiring paired, synchronized data from multiple modalities dramatically reduces available training datasets and complicates real-world deployment logistics [12][14].

---

## 8. Future Directions

1. **Foundation models for pathology and radiology**: Large-scale pre-trained vision transformers (e.g., CONCH, UNI) trained on millions of pathology images are beginning to enable zero-shot and few-shot cancer detection.

2. **Federated learning**: Enables training on distributed hospital datasets without sharing raw patient data, addressing privacy constraints while expanding training cohort diversity.

3. **Liquid biopsy + imaging co-analysis**: Integrating cfDNA methylation profiles with radiological findings in a single AI decision framework represents the next frontier of multimodal oncology.

4. **Prospective MCED trials**: Large-scale trials such as NHS-Galleri (UK) are evaluating blood-based MCED tests in population screening contexts, which will provide the prospective validation currently lacking [10].

5. **Explainable AI (XAI)**: SHAP values, GradCAM, and attention visualization are increasingly integrated into cancer detection pipelines to support clinical decision-making and regulatory approval [7].

6. **Real-world evidence generation**: Post-market surveillance of FDA-cleared AI tools in mammography and lung CT screening is generating real-world performance data that will refine clinical guidelines.

---

## 9. Conclusion

AI-based early cancer detection has demonstrated substantial promise across imaging, genomics, and multimodal paradigms. The evidence synthesized in this report leads to three core conclusions:

1. **Imaging-based AI** is the most clinically mature approach, with population-scale validation and regulatory-cleared tools, but faces challenges in specificity and generalizability.

2. **Genomics-based AI** shows the highest peak performance metrics in controlled studies and offers a pan-cancer, minimally invasive screening concept, but requires large prospective validation before clinical translation.

3. **Multimodal AI** consistently outperforms single-modality approaches (demonstrated gain: +4.5% AUC in lung radiogenomics) and represents the most promising direction for next-generation cancer screening, provided integration complexity and data governance challenges are addressed.

The path forward requires coordinated investment in prospective clinical trials, standardized benchmarking datasets, regulatory frameworks for AI-based diagnostics, and federated infrastructure to enable multi-institutional model development without compromising patient privacy.

---

## 10. References

[1] Yadav, S. K., Kumar, H., & Janu, A. K. (2025). Machine learning in MRI-based cancer characterization: Enhancing precision and early detection. *IJLTEMAS*. https://doi.org/10.51583/ijltemas.2025.1411000094

[2] Gandhi, N., Kheni, D. A., Shirzada, S. A., et al. (2024). Systematic review: Comparing AI-based algorithms and radiologists in identifying lung nodules on CT scans. *International Journal for Multidisciplinary Research*, 6(6). https://doi.org/10.36948/ijfmr.2024.v06i06.30712

[3] McKinney, S. M., Sieniek, M., Godbole, V., et al. (2020). International evaluation of an AI system for breast cancer screening. *Nature*. https://doi.org/10.1038/S41586-019-1799-6

[4] Ciccone, V., Garofano, M., Del Sorbo, R., et al. (2025). Improving early prostate cancer detection through artificial intelligence: Evidence from a systematic review. *Cancers*, 17(21), 3503. https://doi.org/10.3390/cancers17213503

[5] Chen, J., Pan, T., Zhu, Z., et al. (2025). A deep learning-based multimodal medical imaging model for breast cancer screening. *Dental Science Reports / Scientific Reports*. https://doi.org/10.1038/s41598-025-99535-2

[6] Artificial intelligence detection scores in screening mammography for early breast cancer alerts. (2025). *Radiology*. https://doi.org/10.1148/radiol.251309

[7] Sathya, A., Reddy, D. R., & Blessy, J. J. (2025). Genomic and imaging biomarker analysis in lung cancer: A SHAP-guided approach. *Proceedings of ICCDS 2025*. https://doi.org/10.1109/iccds64403.2025.11209732

[8] Karar, M. E., El-Fishawy, N., & Radad, M. A. (2023). Automated classification of urine biomarkers to diagnose pancreatic cancer using 1-D convolutional neural networks. *Journal of Biological Engineering*, 17. https://doi.org/10.1186/s13036-023-00340-0

[9] Decoding spectral perturbations from a SERS artificial nose in serum for early lung cancer detection. (2025). *Analytical Chemistry*. https://doi.org/10.1021/acs.analchem.6c00680

[10] Brito-Rocha, T., Constâncio, V., & Henrique, R., et al. (2023). Shifting the cancer screening paradigm: The rising potential of blood-based multi-cancer early detection tests. *Cells*, 12(6), 935. https://doi.org/10.3390/cells12060935

[11] Rezayi, S., Niakan Kalhori, S. R., & Saeedi, S. (2022). Effectiveness of artificial intelligence for personalized medicine in neoplasms: A systematic review. *BioMed Research International*, 2022, 7842566. https://doi.org/10.1155/2022/7842566

[12] LungGuard: A multimodal deep learning system for early lung cancer detection via fusion of CT imaging, clinical biomarkers, and demographic data. (2025). *Zenodo*. https://doi.org/10.5281/zenodo.17177686

[13] Rattan, S., Swathi, C., Maram, B., et al. (2025). Revolutionizing cervical cancer screening: A multimodal AI approach using visual, genomic and clinical features. *Proceedings of ISAECT 2025*. https://doi.org/10.1109/isaect68904.2025.11318777

[14] Venkata, C., Reddy, R., RaviKanth, G., et al. (2025). Integrative multi-modal framework for enhanced cervical cancer diagnosis using semi-supervised deep learning. *Proceedings of ICPEEV 2025*. https://doi.org/10.1109/icpeev67897.2025.11291564

---

*Report generated by SciSpace Research Agent | Based on 117 peer-reviewed papers from SciSpace, Google Scholar, PubMed, and ArXiv | June 2026*
